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ATP synthesisWe have studied the effects of idebenone on mitochondrial function in cybrids derived from one normal
donor (HQB17) and one patient harboring the G3460A/MT-ND1 mutation of Leber's Hereditary Optic Neu-
ropathy (RJ206); and in XTC.UC1 cells bearing a premature stop codon at aminoacid 101 of MT-ND1 that
hampers complex I assembly. Addition of idebenone to HQB17 cells caused mitochondrial depolarization
and NADH depletion, which were inhibited by cyclosporin (Cs) A and decylubiquinone, suggesting an in-
volvement of the permeability transition pore (PTP). On the other hand, addition of dithiothreitol together
with idebenone did not cause PTP opening and allowed maintenance of the mitochondrial membrane poten-
tial even in the presence of rotenone. Addition of dithiothreitol plus idebenone, or of idebenol, to HQB17,
RJ206 and XTC.UC1 cells sustained membrane potential in intact cells and ATP synthesis in permeabilized
cells even in the presence of rotenone and malonate, and restored a good level of coupled respiration in com-
plex I-deﬁcient XTC.UC1 cells. These ﬁndings demonstrate that idebenol can feed electrons at complex III. If
the quinone is maintained in the reduced state, a task that in some cell types appears to be performed by
dicoumarol-sensitive NAD(P)H:quinone oxidoreductase 1 [Haefeli et al. (2011) PLoS One 6, e17963], electron
transfer to complex III may allow reoxidation of NADH in complex I deﬁciencies.
© 2011 Elsevier B.V. Open access under CC BY license.1. Introduction
Coenzyme Q is a lipophilic molecule mostly, but not exclusively lo-
calized in the inner mitochondrial membrane [1,2]. It is composed of
a redox active benzoquinone ring conjugated to an isoprenoid side
chain whose length may differ among species. In man ubiquinone
contains predominantly 10 isoprenyl units and is designated CoQ10.
CoQ10 shuttles electrons from complex I and II and other ﬂavoprotein
dehydrogenases to complex III of the mitochondrial respiratory chain;
it also functions as a lipid-soluble antioxidant, scavenges reactive oxygenyclosporin; DMEM, Dulbecco's
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 license.species (ROS), and is involved in multiple aspects of cellular metabolism
[1,2].
Primary CoQ10 deﬁciencies are associated with pathogenic muta-
tions affecting genes involved in the biosynthesis of CoQ10, and cause
clinically heterogeneous diseases [2]. Respiratory chain and ATP syn-
thesis defects, ROS production, and apoptosis contribute to disease
pathogenesis, and most patients affected by primary CoQ10 deﬁcien-
cies respond to CoQ10 supplementation [1,3,4]. Because of the prom-
inent role attributed to ROS in the pathogenesis of mitochondrial
diseases, including Friedreich's ataxia; and because of the antioxidant
effect of CoQ10 [5], its possible use in these diseases has been considered
[1,6,7]. Given the fact that CoQ10 is very insoluble, several short-
chain hydrosoluble quinones have been tested, in particular 2,3-
dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebe-
none). Idebenone did not prove useful in CoQ10 deﬁciencies [4];
yet, due to its redox properties and the evidence that it canmediate elec-
tron transfer to respiratory chain complex III in isolated mitochondria
[1,8–12], idebenone has been used in several diseases associated to re-
spiratory chain dysfunction like Leber's hereditary optic neuropathy
(LHON) [13–17], mitochondrial encephalomyopathy with lactic acidosis
and stroke-like episodes (MELAS) [18–20], Leigh syndrome [21], Frie-
dreich's ataxia [6,7,22,23], as well as Huntington's [24] and Alzheimer
disease [25–28]. More recently, a double blind, placebo-controlled, ran-
domized trial with idebenone in LHON patients (RODHOS study) has
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a large case series of LHON patients treated with idebenone during the
acute phase of the disease [30].
Protective effects of idebenone against cell death induced by glu-
tathione depletion have been reported in CEM leukemia cells [31]
and skin ﬁbroblasts from Friedreich's ataxia patients [32], as well as
in staurosporine-induced apoptosis of cultural retinal neurons [33];
yet higher doses of idebenone were cytotoxic to skin ﬁbroblasts de-
rived from both Friedreich's ataxia patients and healthy donors [34].
The recent demonstration that idebenone undergoes reduction by cyto-
solic dicoumarol-sensitive NAD(P)H:quinone oxidoreductase 1 (NQO1)
[35] provides a rationale for its use in complex I-deﬁcient cells, yet po-
tentially toxic effects of idebenonemay depend on inhibition of complex
I itself [8–12] and on opening of the mitochondrial permeability transi-
tion pore (PTP) [36], an inner membrane high-conductance channel in-
volved in cell death [37].
The effects of idebenone have been studied surprisingly little in
cells, in spite of their obvious importance for the potential therapeutic
use of this drug. Here, we present a characterization of themitochondrial
effects of idebenone in human osteosarcoma-derived cybrids bearing
wild-type mtDNA (HQB17) or the missense G3460A/MT-ND1 mutation
of LHON (RJ206) [38,39]; and in XTC.UC1 cells bearing a truncating mu-
tation in the same gene that hampers complex I assembly [40,41].
2. Materials and methods
2.1. Materials
Oligomycin, rotenone, antimycin A, malonate, malate, pyruvate,
carbonylcyanide-p-triﬂuoromethoxyphenyl hydrazone (FCCP), decylu-
biquinone, dithiothreitol (DTT), ATP monitoring kit, P1,P5 - di(adeno-
sine-5′) pentaphosphate pentasodium and protease inhibitors were
from Sigma (Milan, Italy). Idebenone was from Apin Chemicals LTD
(Oxon, UK). CsA was purchased from Calbiochem, whereas CsH was a
generous gift of Dr. Urs Ruegg, Geneva. CalciumGreen 5Nwas from Invi-
trogen (Milan, Italy). Tetramethylrhodamine methyl ester (TMRM) was
purchased from Molecular Probes (Eugene, OR).
2.2. Isolation of mitochondria and swelling measurements
Mouse liver mitochondria were isolated in a buffer containing
250 mM sucrose, 10 mM Tris, 0.1 mM EGTA, pH 7.4, as described pre-
viously [42]. Swellingwasmonitored as the decrease of 90° light scatter-
ing of the mitochondrial suspension at 545 nm with a Perkin-Elmer
650–40 ﬂuorescence spectroﬂuorimeter equipped with magnetic stir-
ring and thermostatic control.
2.3. Measurements of calcium retention capacity
The mitochondrial Ca2+ retention capacity (CRC) was determined
by measuring external Ca2+ following addition of 10 μM Ca2+ pulses
eachminute tomedium containing 0.5 mg/ml ofmitochondria. External
Ca2+ concentration was measured ﬂuorimetrically in the presence of
1 μMCalcium Green 5 N, a membrane impermeant Ca2+ probe increas-
ing its ﬂuorescence upon Ca2+ binding (excitation and emission wave-
lengths 503 and 525 nm, respectively). The CRC is the amount of Ca2+
taken up bymitochondria before the precipitous release that follows oc-
currence of the permeability transition. The CRC values observed at a
given concentration of idebenone were normalized to the CRC obtained
in the absence of the compound (CRC0).
2.4. Cell culture and growth conditions
HQB17 and RJ206 cells cybrids were generated by fusion of enu-
cleated ﬁbroblasts derived from one control (HQB17) and one LHON
patient (RJ206, a kind gift of Anthony H. Schapira) into osteosarcoma143B.Tk− cells deprived of their own mtDNA [43]. Complete mtDNA
sequencing revealed that HQB17 belongs to haplogroup J1b (Antonio
Torroni, personal communication). RJ206 cells harbor the G3460A/
MT-ND1 LHON mutation causing the A52T amino acid substitution
in MT-ND1 [38,39], which was reported to sharply reduce mitochon-
drial ATP synthesis driven by complex I substrates [44]. XTC.UC1 cells,
derived from a human thyroid carcinoma, bear a C insertion at
bp3571 in MT-ND1, generating a premature stop codon at amino
acid 101 of ND1 subunit that prevents complex I assembly [40,41].
Cells were grown in Dulbecco's modiﬁed Eagle's medium (DMEM)
containing 10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml
penicillin, and 100 g/ml streptomycin in a humidiﬁed incubator at
37 °C with 5% CO2.
2.5. Mitochondrial membrane potential
Mitochondrial membrane potential (Δψm) in isolated organelles
was measured using a Perkin-Elmer LS50B spectroﬂuorometer and
evaluated based on the ﬂuorescence quenching of Rhodamine 123.
Mitochondria (0.5 mg/ml) were added to 2 ml of 130 mM KCl,
10 mM MOPS-Tris, 1 mM Pi-Tris, 10 μM EGTA, 0.15 μM Rhodamine
123, pH 7.4. The ﬂuorescence of Rhodamine 123 was monitored at ex-
citation and emission wavelengths of 503 and 523 nm, respectively,
with the slit width set at 2.5 nm. After a short incubation to reach stabi-
lization of the signal, further additions were as indicated in the legend
to Fig. 1.
For measurements of Δψm in situ, cells were seeded onto 24 mm-
diameter round glass coverslips and grown for 2 days in DMEM. Δψm
was measured based on the accumulation of TMRM in the presence of
1.6 μM CsH, which inhibits the multidrug resistance pump but not the
PTP [42,45]. Cells were incubated in bicarbonate- and phenol red-free
Hank's balanced salt solution (Sigma) supplemented with 10 mM
Hepes and 1.6 μM CsH and loaded with 20 nM TMRM for 30 min. At
the end of each experiment, mitochondria were fully depolarized
by the addition of 4 μM of the protonophore carbonylcyanide-p-
triﬂuoromethoxyphenyl hydrazone (FCCP). Cellular ﬂuorescence im-
ages were acquired with an Olympus IX71/IX51 inverted microscope
equippedwith a xenon light source (150W) for epiﬂuorescence illumi-
nation and with a digital camera. For detection of ﬂuorescence 568±
25 nmbandpass excitation and 585 nm longpass emissionﬁlter settings
were used. Images were collected with an exposure time of 100 ms (6%
illumination intensity) using a 40X, 1.3 NA oil immersion objective
(Olympus). Data were acquired and analyzed using Cell R software
(Olympus). Clusters of several mitochondria (10–30) were identiﬁed
as regions of interest, and ﬁelds not containing cells were taken as the
background. Sequential digital images were acquired every minute,
and the average ﬂuorescence intensity of all relevant regions was
recorded and stored for subsequent analysis.
2.6. Mitochondrial NAD(P)H
Cells were seeded as described above and incubated in bicarbonate-
and phenol red-free Hank's balanced salt solution supplemented with
10 mM Hepes and 1.6 μM CsH for 30 min. Alamethicin (50 μM) was
added at the end of each experiment to allow complete release of pyri-
dine nucleotides from mitochondria. For detection of ﬂuorescence
340 nm bandpass excitation and 465 nm longpass emission ﬁlter set-
tings were used. Images were collected with an exposure time of
800 ms (100% illumination intensity) using a 40X, 1.3 NA oil immersion
objective (Olympus).
2.7. Oxygen consumption rate
Oxygen consumption rate (OCR) in adherent cells was measured
with an XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica
MA, USA). HQB17 and RJ206 cybrids, and XTC.UC1 cells were seeded in
Fig. 1. Effects of idebenone onmitochondrial membrane potential, Ca2+ retention capac-
ity and volume. A, the incubation medium contained 130 mM KCl, 10 mM MOPS-Tris,
1 mM Pi-Tris, 10 μM EGTA, 0.15 μM Rhodamine 123, pH 7.4 and 0.8 μM CsA (trace b
only); where indicated, 5 mM succinate (Succ), 35 μM Ca2+, 50 μM idebenone (IdB) and
0.5 μMFCCPwere added. B, themitochondrial CRCwas determined following the addition
of 10 μM Ca2+ pulses, and values were normalized to the CRC obtained in the absence of
idebenone (CRC0). Mitochondria were treatedwith the indicated concentrations of idebe-
none in the absence (closed symbols) or presence (open symbols) of 1 mMDTT. C, the incu-
bation medium contained 0.25 M sucrose, 1 mM Pi-Tris, 10 mMMOPS-Tris, 20 μM EGTA-
Tris, 5 mM glutamate-Tris, 2.5 mM malate-Tris. Where indicated 50 μM Ca2+, 20 μM
N-ethylmaleimide (NEM) and 50 μM idebenone (IdB) were added.
Fig. 2. Effects of idebenone, CsA and decylubiquinone on mitochondrial TMRM accu-
mulation and NAD(P)H levels. A, TMRM ﬂuorescence and B, NAD(P)H ﬂuorescence of
HQB17 cells in the absence (open symbols, traces a) or presence of 1.6 μM CsA (closed
squares, traces b) or 50 μM decylubiquinone (closed triangles, traces c). Where indicated
50 μM idebenone (IdB), 4 μM FCCP, 80 μM alamethicin (Ala) and 4 μM rotenone (R) were
added. Data in both panels report one representative experiment of ﬁve (for idebenone
and idebenone plus CsA) or three (idebenone plus decylubiquinone). The maximal S.E.,
which is omitted for clarity, was±10%.
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in 200 μl of DMEM containing 4.5 g/l glucose (DMEM-high glucose) and
incubated at 37 °C in 5% CO2 for 24 h. Assays were initiated by replacing
the growthmedium in eachwell with 670 μl of unbuffered DMEM-high
glucose prewarmed at 37 °C. The cells were incubated at 37 °C for
30 min to allow temperature and pH equilibration. After an OCR base-
line measurement, 70 μl of oligomycin, FCCP, rotenone and antimycin
A were sequentially added to each well to reach ﬁnal concentrations
of 1 μg/ml for oligomycin, 0.2 μM (cybrids) or 0.1 μM (XTC.UC1 cells)
for FCCP, and 1 μM for rotenone and antimycin A. Data are expressed
as pmol of O2 perminute per 2×104 cells. At the endof each experiment
the medium was removed and cells were incubated with 0.1 μM
calcein-AM in 200 μl/well of Hank's balanced salt solution supplemen-
ted with 10 mM Hepes and 1.6 μM CsH for 30 min, at 37 °C. Calcein-
labeled adherent cells were observed with the Olympus IX71/IX51
inverted microscope (excitation and emission 495 and 515 nm, respec-
tively, exposure time 100 ms, 6% illumination intensity) using a 10X, 1.3
NA oil immersion objective (Olympus).
2.8. Mitochondrial ATP synthesis
The rate of mitochondrial ATP synthesis wasmeasured in digitonin-
permeabilized cells incubated in 150 mM KCl, 25 mM Tris–HCl, 2 mM
EDTA, 0.1% BSA, 10 mM K-Pi, 0.1 mMMgCl2, pH 7.4, in the presence of
the inhibitor of adenylate kinase (0.1 mM P1,P5 -di(adenosine-5′) pen-
taphosphate) and of complex I substrates (5 mMmalate and 5 mM py-
ruvate) by using the luciferin/luciferase assay [46], as detailed by the
manufacturer's instructions. Addition of luciferin/luciferase (which
according to Sigma is lyophilizedwithMgSO4) increases theMg2+ con-
centration to a level sufﬁcient to allow activity of the enzyme, but still
low enough tominimize the activity of oligomycin-insensitive ATPases.
Thus, although the measured ATP synthesis rate was entirely of mito-
chondrial origin (as indicated by its full sensitivity to oligomycin) theactual ﬁgures may be underestimated because of the concomitant oc-
currence of ATP-hydrolyzing reactions. The reaction was started by ad-
dition of 0.1 mM ADP and chemiluminescence was determined as a
function of time with a luminometer. The chemiluminescence signal
was calibratedwith an internal ATP standard after addition of 10 μMoli-
gomycin. Data were normalized for citrate synthase activity [47]. Fur-
ther additions are indicated in the ﬁgure legends.
2.9. Statistics
Unless otherwise stated in the ﬁgure legends, each experiment
was repeated 3 times. Data are presented as average±S.E. or, for clarity,
as representative experiments (see ﬁgure legends for details).
3. Results
Following energization with succinate, mitochondria underwent a
small and transient depolarization upon the addition of Ca2+, which
is the expected response to Ca2+ accumulation (Fig. 1A). Subsequent
addition of 50 μM idebenone triggered fast and complete mitochon-
drial depolarization (trace a) which was delayed and partially pre-
vented by CsA (trace b), consistent with the PTP-inducing effects of
idebenone [36]. Idebenone caused the expected decrease of the CRC
[36], a sensitive measure of the propensity of the PTP to open; yet
this effect was fully prevented by pretreatment of mitochondria
with CsA (results not shown) or with DTT (Fig. 1B). The latter ﬁnding
is novel and of some interest, because it suggests that idebenone may
interact with a PTP regulatory site that is sensitive to oxidation-
reduction events. This point was investigated further. Following accu-
mulation of a permissive Ca2+ load isolated mitochondria treated
with idebenone underwent the expected PTP-mediated swelling re-
sponse (Fig. 1C, trace a), while pore opening was prevented by treat-
ment with a low concentration of N-ethylmaleimide (Fig. 1C, trace b),
which we have shown to block PTP-regulating sulfhydryl groups that
are also sensitive to reduction with DTT [48].
We next tested the effects of idebenone on Δψm in intact cells based
on accumulation of TMRM inHQB17 cybrids containing normalmtDNA.
Addition of 50 μM idebenone was followed by a rapid drop of ﬂuores-
cence of TMRM (Fig. 2A, trace a), which indicates fast mitochondrial de-
polarization. This ﬂuorescence decrease was largely prevented by
treatment with both CsA (Fig. 2A, trace b) and decylubiquinone
Fig. 4. Effects of DTT and idebenone on mitochondrial TMRM ﬂuorescence in HQB17 cells.
HQB17 cellswere loadedwith 10 nMTMRM. A, additionswere 2 mMDTT, 5 μMoligomycin
(O), 4 μMrotenone (R), 1 μMantimycin A (AA) and 4 μMFCCP (F); B, additions were 2 mM
DTTplus 50 μMidebenone(DTT+IdB), 5 μMoligomycin (O), 4 μMrotenone (R), 1 μManti-
mycinA (AA) and4 μMFCCP. Data are from three or six independent experiments for panels
A and B, respectively.
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Since prolonged openings of the PTP are followed bymembrane permea-
bilization to pyridine nucleotides [50], we also monitoredmitochondrial
NAD(P)H levels, which were rapidly decreased by the addition of idebe-
none (Fig. 2B, trace a) in a process that was prevented by CsA (Fig. 2B,
trace b) or decylubiquinone (Fig. 2B, trace c) but still inducible with the
pore-forming peptide alamethicin (Fig. 2B). Addition of rotenone after
idebenone or alamethicin was not followed by NAD(P)+ reduction
(Fig. 2B), indicating that PTP opening (or alamethicin addition) causes
the release of mitochondrial pyridine nucleotides rather than just their
oxidation, at variance from treatment with FCCP alone (results not
shown). The PTP-inducing effects of idebenone could be due to increased
production of ROS, which has been shown to occur upon treatement of
submitochondrial particles with this compound [12,51].
The bioenergetic consequences of treatment with idebenone were
also assessed by measurements of oxygen consumption with the sen-
sitive Seahorse technology. Respiration of HQB17 cells was substan-
tially inhibited by oligomycin, indicating a good phosphorylation
capacity; it was stimulated well above basal levels by uncoupler, indi-
cating a large respiratory reserve; and it could be largely inhibited by
rotenone with no further effects of antimycin A (Fig. 3, open symbols).
Addition of 50 μM idebenone was followed by a decreased OCR,
which could no longer be stimulated by FCCP (Fig. 3, gray symbols).
The protective effects of CsA were negligible (Fig. 3, closed symbols),
in spite of preservation of the pyridine nucleotide pool.
We then tested whether the PTP-inducing effects of idebenone ob-
served in isolatedmitochondria could be prevented by reduction with
DTT in cells as well. DTT alone was unable to sustain the membrane
potential after addition of rotenone to oligomycin-treated HQB17
cells (Fig. 4A). Strikingly, however, the addition of DTT plus idebe-
none (i) prevented the depolarizing effects otherwise induced by
the latter (Fig. 4B, compare with Fig. 2A); and (ii) allowed mainte-
nance of the mitochondrial membrane potential after inhibition of
complex I by rotenone, depolarization requiring the addition of anti-
mycin A (Fig. 4B). These results are consistent with electron transfer
to complex III. We assessed whether this effect could be also observed
after treatment of cells with idebenol obtained by reduction of idebe-
none with sodium dithionite [52]. Treatment of HQB17 (Fig. 5A),
RJ206 (Fig. 5B) or XTC.UC1 cells (Fig. 5C) with rotenone plus oligomy-
cin caused a rapid depolarization (open symbols, trace a in all panels)
suggesting that oxidation of idebenol (i.e. generation of idebenone)
causes sensitization of the PTP. Indeed, in the presence of CsA the
Δψm was preserved and depolarization was only observed after the
addition of antimycin A (closed symbols, trace b in all panels), indicat-
ing electron feeding at complex III.Fig. 3. Effects of idebenone on respiration of HQB17 cells. HQB17 cells were incubated
in Seahorse 24-well plates (20,000 cells/well) and respiration measured in the absence
(open circles) or presence of 50 μM idebenone alone (gray circles) or with 1.6 μM CsA
(closed symbols). Where indicated 1 μg/mL oligomycin (O), 0.2 μM FCCP (F), 1 μM rote-
none (R), and 1 μM antimycin A (AA) were added. Data report one representative ex-
periment of three, and the maximal S.E. was±11.3 pmol oxygen/min. OCR, oxygen
consumption rate.The next questions we addressed were whether idebenol can im-
prove respiratory performance in cells where activity of complex I is
compromised, and whether inhibition of complex I occurs in cells
with a normal respiratory function. To answer these questions we
studied respiration of HQB17 (Fig. 6A,A′), RJ206 (Fig. 6B,B′) and XTC.
UC1 cells (Fig. 6C,C′).
In HQB17 cells the addition of idebenol decreased basal respira-
tion, which showed virtually no response to oligomycin, FCCP and ro-
tenone (Fig. 6A; compare with dashed trace for the same experiment
carried out in the absence of idebenol, data taken from Fig. 3). This
behavior presumably reﬂects PTP opening by idebenone which
forms during idebenol oxidation (Fig. 2, see also below). Indeed, addi-
tion of DTT plus idebenone had a marginal effect on basal respiration,
which maintained sensitivity to oligomycin (Fig. 6A′). OCR could not
be stimulated further by FCCP, but it became insensitive to rotenone
while it could be inhibited by antimycin A, consistent with direct
electron transfer to complex III (Fig. 6A′). DTT alone inhibited maxi-
mal respiration, suggesting that the inhibitory effect on complex I
may be caused by DTT rather than idebenol. In the absence of idebe-
nol DTT was unable to sustain respiration after addition of rotenone
(Fig. 6A′).
RJ206 cells displayed a lower OCR thanwild-type cells and a normal
response to oligomycin, but could not be stimulated beyond the initial
rate by FCCP, indicating no reserve respiratory capacity (Fig. 6B). Like
in HQB17 cybrids, treatment with idebenol made respiration totally in-
sensitive to oligomycin, FCCP and rotenone (Fig. 6B). Also in this case,
DTT plus idebenone allowed coupled (i.e. oligomycin-sensitive) respi-
ration to occur in spite of a marked toxicity of DTT alone (Fig. 6B′).
XTC.UC1 cells slightly improved their performance after the addi-
tion of idebenol, and displayed a very remarkable increase of the
oligomycin-sensitive (i.e., phosphorylating) OCR with DTT plus ide-
benone in spite of the inhibitory effect of DTT alone (Fig. 6C′).
We ﬁnally directly assessed the effects of idebenone and idebenol
on ATP production with different substrates and inhibitors. It should
be noted that in these experiments no Ca2+was added thus preventing
PTP opening which is strictly Ca2+-dependent. Remarkably, idebenol
improved ATP synthesis in all cell types, and it allowed oxidative phos-
phorylation to proceed after inhibition of complex I with rotenone and
of succinate dehydrogenasewithmalonate (Fig. 7). The rate of ATP syn-
thesis could not be stimulated further by glycerol-3-phosphate (results
not shown).
4. Discussion
In this study we have characterized the effects of idebenone and
idebenol on mitochondrial bioenergetics. We have shown (i) that ide-
benone induces PTP opening in isolated mitochondria [36] through a
Fig. 5. Effects of idebenol on mitochondrial TMRM ﬂuorescence in HQB17, RJ206 and XTC.UC1 cells. HQB17 (A), RJ206 (B) and XTC.UC1 cells (C) were loaded with 10 nM TMRM in
the absence (open symbols) or presence (closed symbols) of 1.6 μM CsA, and changes in ﬂuorescence were monitored by ﬂuorescence microscopy. Where indicated 50 μM idebenol
(IdBH2), 5 μMoligomycin plus 4 μM rotenone (O+R), 1 μM antimycin A (AA) and 4 μM FCCP were added. Data are from three, eleven and ten independent experiments for panels A,
B, and C, respectively.
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reduction with DTT, an observation that proved instrumental in dis-
secting the complex effects of idebenone and idebenol in intact
cells; (ii) that idebenone induces PTP opening also in intact HQB17
cells; under these circumstances idebenone does not mediate elec-
tron transfer between NAD(P)H and respiratory complex III; and
(iii) that in the presence of DTT added idebenone (which presumably
is fully reduced to idebenol) does not have PTP-inducing effects in
cells and it allows rotenone-insensitive electron transfer to complex
III of the respiratory chain, in a process that profoundly ameliorates
the bioenergetic performance of XTC.UC1 cells lacking complex I. In-
terestingly, idebenol has mixed effects, i.e. it can sensitize the PTP
and/or cause respiratory inhibition presumably because of the idebe-
none generated by its oxidation, as also shown by sensitization of the
PTP to opening (which can be revealed by depolarization following the
addition of oligomycin and rotenone). These results are novel because
the effects of idebenone on mitochondrial bionergetics (speciﬁcally,
the possible occurrence of PTP opening) had never been assessed inFig. 6. Idebenol and DTT-reduced idebenone promote basal respiration in XTC.UC1, but not
(C,C′) was measured in 24-well Seahorse plates (20,000 cells/well). Cells were incubated in
Fig. 3). A–C, cells were supplemented with 50 μM idebenol (closed squares); A′-C′, cells were
circles). Note the different scale in panels A and A′. Data are representative of at least seven
(panel A), 3.1 (panel B), 7.5 (panel C), 9.9 (panel A′), 4.5 (panel B′), 4.3 (panel C′).intact cells; and they are relevant to LHON, a maternally inherited dis-
ease due to primary mitochondrial DNA mutations affecting complex I
[53].
Reduced ATP synthesis and increased oxidative stress are believed
to sensitize retinal ganglion cells to apoptosis, which leads to blindness
[54–57]. Recent evidence suggests that the PTP may be involved in the
pathophysiology of this disease [41], and the possible occurrence of a
permeability transition following treatment with idebenone is there-
fore of major concern, particularly in view of the fact that the prepara-
tion used in clinical trial is the oxidized form of the drug. Our ﬁnding
that DTT plus idebenone is free of PTP-inducing effects and allows
rotenone-insensitive electron transfer to complex III is therefore of in-
terest to the development of treatments useful to bypass the defects
of complex I.
Idebenone strongly activates glycerol phosphate oxidation in
brown adipose tissue mitochondria, an effect that could be traced to
release of the inhibition of glycerol phosphate dehydrogenase by en-
dogenous free fatty acids [58]. We did not observe stimulation of ATPin HQB17 and RJ206 cells. Cellular OCR of HQB17 (A, A′), RJ206 (B,B′) and XTC.UC1 cells
the absence of added quinone (open squares; the dashed trace in panel A is taken from
supplemented with 1 mMDTT (open circles) or 1 mMDTT plus 50 μM idebenone (closed
independent experiments, and the maximal variation (in pmol oxygen/min) was 12.5
Fig. 7. ATP synthesis in permeabilized HQB17, RJ206 and XTC.UC1 cells. HQB17 (A),
RJ206 (B) and XTC.UC1 (C) cells were permeabilized with digitonin and rate of ATP
synthesis was evaluated in the presence of 5 mM pyruvate and 5 mM malate (P/M),
50 μM idebenol (IdBH2), 50 μM idebenone (IdB), 5 μM rotenone and 5 mM malonate
(Rot/Malon) as indicated. Asterisks denote values signiﬁcantly different from P/M
alone (Pb0.05).
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RJ206 and XTC.UC1 cells treated with idebenone (results not shown),
suggesting that idebenone is not reduced by glycerol phosphate dehy-
drogenase in these cells. The possibility that this occurs in other cell
types must, however, be borne in mind.
A pathway for electron transfer from NADH to mitochondria has
recently been identiﬁed with the demonstration that idebenone is a
good substrate of cytosolic dicoumarol-sensitive NQO1 [35]; and
that rescue of ATP levels by idebenone in different cell types correlat-
ed with expression of NQO1, which may provide an effective electron
transfer from cytosolic NAD(P)H to idebenone and then complex III,
thus reducing lactic acidosis in patients with complex I deﬁciency
[35]. Remarkably, administration of 400 mg/kg/day of idebenone to
mice for 4 weeks signiﬁcantly slowed down the depletion of ATP in-
duced by rotenone in isolated hepatocytes that had not been further
treated with the drug [35]. In our cell lines rotenone-insensitive res-
piration in the presence of idebenol was not inhibited by dicoumarol
(results not shown), suggesting that idebenone is not reduced by
NQO1. This is consistent with PTP sensitization and inhibition of res-
piration in the course of idebenol oxidation, which we explain with
generation of idebenone (Figs. 5 and 6).
Besides anecdotal reports on the effects of idebenone therapy in
various conditions [13–17], the largest experience has been on pa-
tients with LHON both through a prospective controlled trial [29]
and a retrospective re-evaluation of large cohorts of treated patients
[30]. These studies revealed some efﬁcacy although a subclass of pa-
tients is poor responders [29,30]. The pathogenic mechanism of the
different LHON mutations, which has not been fully elucidated yet,
may be relevant to the variable success of idebenone in compensating
complex I dysfunction. Furthermore, it should bementioned that genet-
ic variation in NQO1 [59,60], as well as in mtDNA haplogroups poten-
tially regulating respiratory chain coupling and antioxidant enzymes,
are putative modiﬁers of the therapeutic response to idebenone in
LHON.
The in vivo studies provided encouraging clinical evidence that
idebenone is safe and well tolerated. Since idebenone is transformed
into its metabolites QS-10, QS-6 and QS-4 within minutes of adminis-
tration, and parent idebenone is not detectable in plasma after about
1 h [22,61], we suspect that the beneﬁcial effects are not due to idebe-
none itself but to one of its longer-lasting metabolites. An attractive
candidate appeared to be the carboxy derivative QS-10, which is a
good electron acceptor from NQO1; yet QS-10 failed to restore ATP
levels and to decrease lactate production in MELAS cells [35]. It will
be important to test the mitochondrial effects of idebenone metabo-
lites in order to identify the active species, a strategy that shouldprovide effective and safer compounds devoid of the potentially
toxic PTP-inducing properties of idebenone [36,62].Acknowledgments
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